Seemann et al. investigated PRs for the treatment of FD, which resulted in the identification of small molecules (proteasome inhibitors such as MG132, BTZ, and CLC and an inhibitor of the ERAD) able to increase mutant GLA activity in patient-derived fibroblasts [60]. The gene discussed is WNK3; the disease is Fabry disease.